Edward van Wezel
President at Biogeneration Management BV
Network origin in Edward van Wezel first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Biogeneration Management BV
 Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.
15
| Subsidiary | Investment Managers | 15 |
Stichting Publieke Private Samenwerking Versterking
 Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands.
11
| Foundation/Endowment | Investment Trusts/Mutual Funds | 11 |
Scenic Biotech BV
 Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.
11
| Holding Company | Miscellaneous Commercial Services | 11 |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.
8
| Holding Company | Pharmaceuticals: Major | 8 |
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands.
7
| Subsidiary | Biotechnology | 7 |
TigaTx, Inc.
 TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer.
7
| Holding Company | Biotechnology | 7 |
Escalier Biosciences BV
 Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands.
5
| Holding Company | Biotechnology | 5 |
TigaTx BV
 TigaTx BV Miscellaneous Commercial ServicesCommercial Services TigaTx BV is a Dutch company that provides research and development in the field of health nutrition. The company is based in Utrecht, the Netherlands. The company was founded in 2020 by Jeanette Leusen.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Genase Therapeutics BV
 Genase Therapeutics BV Pharmaceuticals: MajorHealth Technology Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Edward van Wezel via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| Vimalan Biosciences, Inc. | Corporate Officer/Principal Director/Board Member Chief Tech/Sci/R&D Officer Founder | ||
Oppilan Pharma Ltd.
 Oppilan Pharma Ltd. BiotechnologyHealth Technology Oppilan Pharma Ltd. operates as a biotechnology company. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Founder | |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member | |
| VENTYX BIOSCIENCES, INC. | Biotechnology | Corporate Officer/Principal Director/Board Member Chief Tech/Sci/R&D Officer Founder | |
| University of Utrecht | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Founder Private Equity Investor Director of Finance/CFO | |
Akarna Therapeutics Ltd.
 Akarna Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Akarna Therapeutics Ltd. develops novel small molecule therapeutics. It offers non-bile acid FXR agonist, a therapeutic for the treatment of nonalcoholic steatohepatitis and fatty-liver diseases. The company was founded by Raju Mohan in 2014 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Generic | Corporate Officer/Principal Director/Board Member Founder | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Analyst | |
| University of Leiden | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
INKEF Capital BV
 INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Analyst | |
New Science Ventures LLC
 New Science Ventures LLC Investment ManagersFinance New Science Ventures LLC (New Science Ventures) is a venture capital firm founded in 2004 by Somasundaram Subramaniam and Tom J A Lavin. The firm is headquartered in Greenwich, Connecticut with additional office in London. | Investment Managers | Founder Private Equity Investor | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
Precirix NV
 Precirix NV Pharmaceuticals: MajorHealth Technology Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Wisconsin | College/University | Doctorate Degree Undergraduate Degree | |
Mellon Medical BV
 Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
| EXELIXIS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Strasbourg | College/University | Doctorate Degree Doctorate Degree | |
SurgVision BV
 SurgVision BV Medical SpecialtiesHealth Technology SurgVision BV provides optical imaging camera systems. It develops integrated optical imaging platforms, including camera, software and target specific tracer, for specific disease areas like breast cancer surgery. The company was founded by Vasilis Ntziachristos and Ton van den Hoven in 2011 and is headquartered in 't Harde, the Netherlands. | Medical Specialties | Director/Board Member Chairman | |
Syndesi Therapeutics SA
 Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Zomagen Biosciences Ltd. | Corporate Officer/Principal Founder | ||
LimmaTech Biologics AG
 LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Founder Founder | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Radboud University Nijmegen | College/University | Corporate Officer/Principal Graduate Degree | |
Draupnir Bio ApS
 Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member Chief Executive Officer | |
| University of Groningen | College/University | Doctorate Degree Graduate Degree | |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Participatiemaatschappij Vlaanderen NV
 Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree | |
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Luciole Medical AG
 Luciole Medical AG Packaged SoftwareTechnology Services Luciole Medical AG operates as a Swiss medical technology company developing brain oxygenation monitoring systems. The firm's products include Rheopatch, RheoSens, RheoLity and RheoControl. The company was founded in September 2017 and is headquartered in Zurich, Switzerland. | Packaged Software | Director/Board Member Chief Executive Officer | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Technische Universiteit Eindhoven | College/University | Undergraduate Degree Undergraduate Degree | |
iOnctura SA
 iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Rgenta Therapeutics, Inc.
 Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Miscellaneous Commercial Services | Director/Board Member | |
Abexxa Biologics, Inc.
 Abexxa Biologics, Inc. Pharmaceuticals: MajorHealth Technology AbeXXa Biologics, Inc. is engaged in biopharmaceutical services. The company was founded by Jon Weidanz and Debra Weidanz in 2015 and is headquartered in Arlington, TX. | Pharmaceuticals: Major | Director/Board Member | |
Vedanta Biosciences, Inc.
 Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
| The University of Chicago | College/University | Doctorate Degree | |
| EDITAS MEDICINE, INC. | Biotechnology | Chief Operating Officer |
Statistics
International
| United States | 19 |
| Netherlands | 14 |
| United Kingdom | 5 |
| Belgium | 5 |
| Switzerland | 5 |
Sectoral
| Health Technology | 25 |
| Consumer Services | 12 |
| Commercial Services | 7 |
| Finance | 7 |
| Technology Services | 2 |
Operational
| Director/Board Member | 280 |
| Corporate Officer/Principal | 70 |
| Private Equity Investor | 46 |
| Chairman | 37 |
| Founder | 35 |
Most connected contacts
| Insiders | |
|---|---|
| Somu Subramaniam | 49 |
| Norman Selby | 32 |
| Stéphane Verdood | 32 |
| Dieter Weinand | 32 |
| Stephan Christgau | 29 |
| Roel Bulthuis | 29 |
| Christopher Krueger | 20 |
| Philippe Dro | 18 |
| Alexander Vos | 17 |
| Karl Nägler | 16 |
| Alexandra Tolia | 15 |
| Robert Scott | 15 |
| Christina Takke | 14 |
| Bart Bergstein | 12 |
| Filip Goossens | 11 |
- Stock Market
- Insiders
- Edward van Wezel
- Company connections
